109 related articles for article (PubMed ID: 16679089)
1. Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome.
Kamalesh M; Rao R; Sawada S; Friend A; Schellhase E; Evans T
Am J Cardiol; 2006 May; 97(10):1487-9. PubMed ID: 16679089
[TBL] [Abstract][Full Text] [Related]
2. Hypercholesterolemia. The evidence supports use of statins.
Aronow WS
Geriatrics; 2003 Aug; 58(8):18-20, 26-8, 31-2. PubMed ID: 12938249
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
4. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
[TBL] [Abstract][Full Text] [Related]
5. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
8. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe plus simvastatin cardiovascular outcomes study program.
Padial LR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
[TBL] [Abstract][Full Text] [Related]
11. Statins enhance circulating vitamin E.
Cangemi R; Loffredo L; Carnevale R; Pignatelli P; Violi F
Int J Cardiol; 2008 Jan; 123(2):172-4. PubMed ID: 17306387
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
13. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
15. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
Faergeman O; Holme I; Fayyad R; Bhatia S; Grundy SM; Kastelein JJ; LaRosa JC; Larsen ML; Lindahl C; Olsson AG; Tikkanen MJ; Waters DD; Pedersen TR;
Am J Cardiol; 2009 Aug; 104(4):459-63. PubMed ID: 19660594
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
[TBL] [Abstract][Full Text] [Related]
17. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
18. The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study.
Coccia R; Spadaccio C; Foppoli C; Perluigi M; Covino E; Lusini M; Chello M
Clin Ther; 2007 Aug; 29(8):1706-17. PubMed ID: 17919551
[TBL] [Abstract][Full Text] [Related]
19. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage.
Kramer AH; Gurka MJ; Nathan B; Dumont AS; Kassell NF; Bleck TP
Neurosurgery; 2008 Feb; 62(2):422-7; discussion 427-30. PubMed ID: 18382320
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
